Jennison and Novak Families Professor of Neurosurgery; Director, Meningioma Center; Professor of Neurosurgery; Professor of Oncology
Johns Hopkins University School of Medicine
Identify key genetic pathways that are altered in brain tumors; Developing clinical trials to selectively target these pathways; Developing targeted therapies for patients with primary and metastatic tumors of the brain and spine; Ongoing clinical protocol to develop a simple blood test that can detect and monitor disease burden in patients with tumors affecting the central nervous system.
Released Tumor DNA in the CSF for the Diagnosis and Monitoring of Pediatric Brain Tumors
One of the challenges in neuro-oncology, which is particularly germane to the pediatric population, is the lack of robust biomarkers that can be used to monitor disease burden. The primary modality for diagnosing disease onset, persistence or progression is radiographic imaging with computed tomo
Determining Prognostic Factors and Genetic Markers that Impact Survival in Recurrent Pediatric Medulloblastoma
Medulloblastoma is the most common malignant brain tumor in children under 18 years of age. It is classified as World Health Organization (WHO) grade IV. Four different subgroups of medulloblastomas—WNT, SHH, Group 3, and Group 4—have been identified based on molecular characteristics. Today, med
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinic